Loading…
Accretion Pharmaceuticals (ACCPL)₹203.15−3.26%Pharmaceuticals
Accretion Pharmaceuticals is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 23.3 against a peer median of 23.3, and ROCE of 28.9% against a peer median of 12.0%, and latest-quarter sales growth of 18.2% against a peer median of 19.2%. By market cap it is #6 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Everest Organics | 255 | 44.6 | 12.0 | 7.6 | 0.66 | 0.0 | 196 | 6 | 19.2 | −9.7 | vs ACCPL |
| Sat Kartar Life | 245 | 14.2 | 36.0 | 26.5 | 0.04 | 0.5 | 201 | 17 | 26.7 | 28.4 | vs ACCPL |
| BDH Industries | 240 | 22.1 | 19.9 | 14.8 | 0.03 | 1.2 | 96 | 11 | 62.8 | 15.6 | vs ACCPL |
| Zenotech Laboratories | 238 | — | 4.6 | −1.2 | 0.00 | 0.0 | 44 | −1 | 10.2 | −145.0 | vs ACCPL |
| Accretion Nutraveda | 237 | 47.2 | 27.8 | 25.1 | 0.12 | 0.0 | 34 | 5 | 80.4 | 56.1 | vs ACCPL |
| Accretion Pharmaceuticals | 225 | 23.3 | 28.9 | 27.6 | 0.23 | 0.0 | 89 | 10 | 18.2 | 13.9 | — |
| Gennex Laboratories | 218 | 11.2 | 11.0 | 9.2 | 0.36 | 0.0 | 173 | 21 | 16.5 | −6.8 | vs ACCPL |
| Sanjivani Paranteral | 214 | 28.8 | 18.0 | 15.6 | 0.30 | 0.3 | 69 | 7 | 33.3 | 44.2 | vs ACCPL |
| Kerala Ayurveda | 212 | — | −10.0 | −161.1 | 7.83 | 0.0 | 131 | −16 | 15.9 | −500.5 | vs ACCPL |
| Nectar Lifesciences | 198 | — | 0.0 | −31.3 | 0.00 | 0.0 | 0 | −293 | −100.0 | — | vs ACCPL |
| Achyut Healthcare | 195 | — | 1.2 | 1.0 | 0.01 | — | 12 | 0 | 381.3 | −46.2 | vs ACCPL |
| Peer median | 225 | 23.3 | 12.0 | 9.2 | 0.12 | 0.0 | 89 | 6 | 19.2 | 3.6 |
Listed companies closest to Accretion Pharmaceuticals in Pharmaceuticals include Everest Organics, Sat Kartar Life, BDH Industries, Zenotech Laboratories, Accretion Nutraveda, Gennex Laboratories, Sanjivani Paranteral, Kerala Ayurveda.
Everest Organics, with a market cap of ₹255 Cr.
Accretion Pharmaceuticals trades at a P/E of 23.3; the median of its peer set is 23.3. A P/E above or below the median is a description, not a judgement on value.
Accretion Pharmaceuticals' return on capital employed is 28.9%, above the peer median of 12.0%.